Amneal Launches Brekiya®, First and Only DHE Autoinjector for Migraine and Cluster Headaches
Amneal Pharmaceuticals, Inc. has launched Brekiya® (dihydroergotamine mesylate) injection in the United States, the first and only ready-to-use DHE autoinjector approved for the acute treatment of migraine with or without aura and cluster headaches in adults.
The autoinjector is available by prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy.
Migraine affects about 43 million Americans, and roughly 300,000 people experience cluster headaches.
These conditions are among the most common reasons for emergency department visits in the U.S. Brekiya® offers a convenient, self-administered treatment option that may help patients manage severe headache attacks more effectively and reduce the need for emergency care.
Brekiya® is available only by prescription, with eligible commercially insured patients paying as little as $40 per carton containing four single-dose autoinjectors.
Amneal will support healthcare providers through reimbursement assistance and patient access programmes.
The medicine must not be used with strong CYP3A4 inhibitors, including protease inhibitors and macrolide antibiotics, due to the risk of serious reductions in blood flow.
It is also unsuitable for patients with heart disease, uncontrolled hypertension, vascular conditions, severe liver or kidney problems, or those who have recently used certain migraine or blood vessel–constricting medications.
